Canada, EU To Probe Novartis Diabetes Drug

Law360, New York (December 22, 2011, 7:56 PM ET) -- European and Canadian heath regulators are investigating a Novartis AG diabetes drug and advising doctors to stop prescribing it in combination with two other types of drugs for the time being, the regulators announced Thursday.

The European Medicines Agency and Health Canada said they are investigating all diabetes drug brands containing aliskiren after pharmaceutical giant Novartis' Tuesday announcement that it was halting a study involving the drug because of potential dangers.

Aliskiren was approved in 2007 in the EU and U.S. under the brand names Rasilez...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required